Correspondence | Published:

An end to the search for new drugs?

Nature volume 296, pages 387390 (01 April 1982) | Download Citation

Subjects

Abstract

Public demand for totally safe drugs has led to excessive, costly and misleading toxicity testing. Such testing drains the resources which have been available for discovering much needed new drugs. Better public understanding of the limitations of toxicity testing and the hazards of medication is sorely needed in order to improve the prospects for diseases still needing effective treatments.

References

  1. 1.

    Nature 283, 609 (1980).

  2. 2.

    Br. med. J. ii, 670 (1980).

  3. 3.

    & Nature 284, 118 (1980).

  4. 4.

    Br. med. J. i, 1618–1619 (1978).

  5. 5.

    , & Clin. Pharmac. Ther. 28, 270–277 (1980).

  6. 6.

    in Risk-Benefit Analysis in Drug Research (ed. Cavalla, J. F.) 17–25 (MTP Press, Lancaster, 1981).

  7. 7.

    Br. med. J. ii, 710–702, (1975).

  8. 8.

    Regulation 3, 27–32 (1979).

  9. 9.

    Br. med. J. i, 1486 (1978).

  10. 10.

    in Risk-Benefit Analysis in Drug Research (ed. Cavalla, J. F.) 179–184 (MTP Press, Lancaster, 1981).

  11. 11.

    Acta pharm. suecica 10, 401 (1973).

  12. 12.

    Medicine, Baltimore 59, 79–99 (1980).

  13. 13.

    , , & Br. med. J. ii, 1461–1466 (1979).

  14. 14.

    Clin. Pharmac. Ther. 15, 73–96 (1974).

  15. 15.

    Trans. R. Soc. trap. Med. Hyg. 73, 147–149 (1979).

  16. 16.

    Br. med. Bull. 29, 172–178 (1973).

  17. 17.

    clin. Invest. 57, 1148–1157 (1976).

  18. 18.

    , & Br. med. J. ii, 1326–1328 (1979).

  19. 19.

    , & Br. med. Bull. 34, 279–284 (1978).

  20. 20.

    J. R. Soc. Med. 73, 405–407 (1980).

  21. 21.

    Perspectives Biol. Med. 21, 167–195 (1979).

  22. 22.

    Cancer Res. 29, 1895–1903 (1969).

  23. 23.

    Eur. J. clin. Pharmac. 11, 233–238 (1978).

  24. 24.

    Br. J. prev. soc. Med. 29, 157–169 (1975).

  25. 25.

    Trans. Am. Ophth. Soc. 65, 494–543 (1967).

  26. 26.

    Br. med. J. i, 595–598 (1975).

  27. 27.

    & Int. J. clin. Pharmac. 16, 479–481 (1978).

  28. 28.

    , , , & Acta psychiatr. scand. 56, 241–248 (1977).

  29. 29.

    & Eur. J. clin. Pharmac. 11, 199–201 (1977).

  30. 30.

    Anaesthetist 15, 13–18 (1966).

  31. 31.

    & Ann. N.Y. Acad. Sci. 151, 777–794 (1968).

  32. 32.

    et al. Lancet i, 1107–1109 (1980).

  33. 33.

    J. Am. med. Ass. 177, 104–108 (1961).

  34. 34.

    Proc. Eur. Soc. Study Drug Toxic. ii, 57–64 (1963).

  35. 35.

    in Drug Responses in Man (eds Wolstenholme, G. & Porter, R.) 247–249 (Churchill, London, 1967).

  36. 36.

    J. R. Soc. Med. 71, 693–696 (1978).

  37. 37.

    , , & Nature 251, 508–510 (1974).

  38. 38.

    , , , & J. Pharmac. exp. Ther. 199, 41–52 (1976).

  39. 39.

    , & J. int. med. Res. i, 489–503 (1973).

  40. 40.

    Br. med. J. i, 947 (1959).

  41. 41.

    , & Br. med. J. i, 1593–1594 (1964).

  42. 42.

    & Food Cosmet. Tox. 4, 297–320 (1966).

  43. 43.

    Br. med. J. i, 683–685 (1978).

  44. 44.

    in Drug Metabolism (eds Parke, D. V. & Smith, R. L.) 147–186 (Taylor and Francis, London, 1976).

  45. 45.

    First Report of the Expert Committee on Drug Toxicity ( Association of the British Pharmaceutical Industry, London, 1964).

  46. 46.

    Long Term Toxic Effects, a Study Group Report (The Royal Society, London, 1978).

  47. 47.

    & Nature 274, 20–21 (1978).

  48. 48.

    & Nature 274, 19–20 (1978).

  49. 49.

    & in Chemical Carcinogens and DNA Vol. 2 (ed. Grover, P. L.) 133–158 (CRC Press, Boca Raton, Florida, 1979).

  50. 50.

    Clin. Tox. 14, 133–139 (1979).

  51. 51.

    Mutat. Res. 68, 41–49 (1979).

  52. 52.

    , , & Mutat. Res. 68, 101–106 (1979).

  53. 53.

    & Am. J. pub. Hlth 70, 276–278 (1980).

  54. 54.

    & Mutat. Res. 77, 185–188 (1980).

  55. 55.

    A. Rev. Med. 26, 203–217 (1975).

  56. 56.

    Am. J. Ophthal. 62, 412–435 (1966).

  57. 57.

    , , , & New Engl. J. Med. 304, 630–633 (1981).

  58. 58.

    Science 203, 6–7 (1979).

  59. 59.

    Lancet i, 981 (1979).

  60. 60.

    Mutat. Res. 67, 193–196 (1979).

  61. 61.

    Tox. Lett. 4, 15–19 (1979).

  62. 62.

    Pharm. J. 224, 493, 505 (1980) 226, 417 (1981).

  63. 63.

    Br. med. J. 284, 249–254 (1982).

  64. 64.

    Proc. R. Soc. Med. 69, 105–107 (1976).

  65. 65.

    & Br. med. J. i, 96–97 (1977).

  66. 66.

    Br. med. J. 282, 1131–1132, 1216–1217 (1981).

  67. 67.

    & Br. J. clin. Pharmac. 12, 453–463 (1981).

  68. 68.

    Proc. R. Soc. Med. 69, 107–113 (1976).

  69. 69.

    Proc. R. Soc. A316, 5–16 (1981).

  70. 70.

    Clin. Pharmac. Ther. 24, 499–524 (1978).

  71. 71.

    Regulation 3, 25–33 (1979).

  72. 72.

    Perspectives Biol. Med. 22, 185–204 (1979).

  73. 73.

    , & Br. med. Bull. 26, 203–207 (1970).

Download references

Author information

Affiliations

  1. Dr. Miles Weatherall was Director of Establishment, Wellcome Research Laboratories, Beckenham, Kent until, 1979. Present address: Willows, Church Lane, Charlbury, Oxfordshire OX7 3PX, UK

    • M. Weatherall

Authors

  1. Search for M. Weatherall in:

About this article

Publication history

Published

DOI

https://doi.org/10.1038/296387a0

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing